Home › Neurologic Diseases › Texas › Austin
Neurologic Diseases clinical trials in Austin, TX
5 studies for Neurologic Diseases are looking for participants at sites in and around Austin (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Investigate the Effects of Cleminorexton Compared With Placebo in the Treatment of Participants With Central Disorders of Hypersomnolence
RecruitingPhase 2/3
- Austin, Texas, Austin
A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis
RecruitingPhase 2
- Clinical Site, Austin
Product Surveillance Registry
RecruitingObservational study
- Austin, Austin
- Kyle, Kyle · 21 mi away
A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
RecruitingPhase 2
- Clinical Site, Austin
Music-4-MS to Improve Cognition in People Living With Multiple Sclerosis: A Feasibility Study
Recruiting
- University of Texas at Austin, Austin
About Neurologic Diseases
Your nervous system includes your brain, spinal cord, and nerves. Learn about neurologic diseases, including their symptoms, causes, and treatments.
More about Neurologic Diseases on MedlinePlus
Neurologic Diseases trials in other cities
- Boston, MA10 studies
- Washington, DC8 studies
- Miami, FL7 studies
- Philadelphia, PA7 studies
- Orlando, FL7 studies
- Dallas, TX7 studies
- St. Louis, MO6 studies
- Houston, TX6 studies
- San Diego, CA6 studies
- New York City, NY6 studies
- Chicago, IL6 studies
- Pittsburgh, PA5 studies
Other studies in Austin
- Non-Small Cell Lung Cancer30 studies
- Cancer (all types)20 studies
- Obesity20 studies
- Metastatic Cancer19 studies
- Colorectal Cancer19 studies
- Heart Failure18 studies
- Breast Cancer18 studies
- Overweight18 studies
- Ovarian Cancer17 studies
- Endometrial Cancer15 studies
- Prostate Cancer15 studies
- Depression14 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.